United States (Houston) Archives

The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects

1 April 2009

David L. Schwartz, Garth Powis, Arun Thitai-Kumar, Yi He, James Bankson, Ryan Williams, Robert Lemos, Junghwan Oh, Andrei Volgin, Suren Soghomonyan, Ryuichi Nishii, Mian Alauddin, Uday Mukhopadhay, Zhenghong Peng, William Bornmann, and Juri Gelovani

CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure

1 February 2009

By Nevena Djuranovic

Michael Fiegl, Ismael Samudio, Karen Clise-Dwyer, Jared K. Burks, Zakar Mnjoyan, and Michael Andreeff

Hypoxia-Associated Factor, a Novel E3-Ubiquitin Ligase, Binds and Ubiquitinates Hypoxia-Inducible Factor 1α, Leading to Its Oxygen-Independent Degradation

1 December 2008

By Nevena Djuranovic

Mei Yee Koh, Bryant G. Darnay, and Garth Powis

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α

1 January 2008

By Nevena Djuranovic

Mei Y. Koh, Taly Spivak-Kroizman, Sara Venturini, Sarah Welsh, Ryan R. Williams, D. Lynn Kirkpatrick, and Garth Powis

Applications

Solutions

United States (Houston)

The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects

CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure

Hypoxia-Associated Factor, a Novel E3-Ubiquitin Ligase, Binds and Ubiquitinates Hypoxia-Inducible Factor 1α, Leading to Its Oxygen-Independent Degradation

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α